Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
RSV season in most of the United States begins in the fall, usually October or November, and continues through spring, often tapering off in April or May. Cases typically peak between December and February, though timing varies by region, with Florida and tropical climates seeing earlier and longer seasons. Several factors influence when RSV circulates and how severe it gets, including age, location, and year-to-year variation, so review the complete details below before assuming your symptoms are simply seasonal. Because RSV can look identical to a common cold, the flu, or COVID-19, yet poses real risk to infants, older adults, and people with heart or lung conditions, guessing is not a safe strategy. Take a free, instant, online symptom check to get clarity on what may be causing your symptoms and understand the right next steps.
Last reviewed for medical accuracy: 09/23/2026
Respiratory Syncytial Virus (RSV) is a common respiratory virus that can cause mild, cold-like symptoms in most people but can be serious for infants, older adults, and those with weakened immune systems. Understanding when RSV season starts, peaks, and ends can help you take steps to protect yourself and your loved ones.
RSV is a highly contagious virus that infects the lungs and breathing passages.
RSV activity follows a seasonal pattern, although exact timing can vary by region and year. In the United States:
In other parts of the world, RSV season often coincides with cooler or rainy months. For example:
Peak RSV activity generally occurs in the heart of winter:
Keep in mind:
Knowing when RSV is most active helps you prepare:
RSV symptoms typically appear 4–6 days after exposure and can include:
Most healthy older children and adults recover in 1–2 weeks. Infants and high-risk groups may need medical attention if symptoms worsen.
During RSV season, simple habits can lower the chance of infection and spread:
To know exactly when RSV season starts and peaks near you, consider:
Most RSV infections are manageable at home, but seek prompt medical attention if you notice any of the following:
In adults, seek care if you have severe difficulty breathing, chest pain, or confusion.
If you’re unsure whether your symptoms warrant medical attention, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s an easy way to evaluate your symptoms and decide on next steps.
Always discuss any concerns or worrisome symptoms with a healthcare professional. If your child or you have serious breathing problems, signs of dehydration, or other life-threatening symptoms, please seek emergency care or call your local emergency number immediately.
Key reminders:
Staying aware of RSV season and knowing the peak activity periods can help you protect yourself and those around you. If you have any doubts or your symptoms worsen, reach out to your healthcare provider without delay.
(References)
* Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus Seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):71-76. doi: 10.15585/mmwr.mm6702a4. Epub 2018 Jan 19. PMID: 29346336; PMCID: PMC5772804.
* Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019 Sep 10;366:l5021. doi: 10.1136/bmj.l5021. Epub 2019 Sep 10. PMID: 31506273.
* Wrotek A, Czajkowska M, Jackowska T. Seasonality of Respiratory Syncytial Virus Hospitalization. Adv Exp Med Biol. 2020;1279:93-100. doi: 10.1007/5584_2020_503. PMID: 32170670.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669.
* Guo L, Deng S, Sun S, Wang X, Li Y. Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis. Lancet Glob Health. 2024 Jun;12(6):e1005-e1016. doi: 10.1016/S2214-109X(24)00090-1. Epub 2024 Apr 23. PMID: 38670132.
* Walsh EE, Eiras D, Woodside J, Jiang Q, Patton M, Marc GP, Llapur C, Rämet M, Fukushima Y, Hussen N, Cardona J, Mikati T, Zareba A, Ilangovan K, Lino MM, Kalinina EV, Swanson KA, Gurtman A, Munjal I. Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2026 Feb 4;81(6):e680-e689. doi: 10.1093/cid/ciaf061. PMID: 39928572.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 study group. Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14. PMID: 40245915.
* Torres JP, Sauré D, Goic M, Thraves C, Pacheco J, Burgos J, Trigo N, Del Solar F, Neira I, Díaz G, O'Ryan M, Basso LJ. Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study. Lancet Infect Dis. 2025 Nov;25(11):1189-1198. doi: 10.1016/S1473-3099(25)00233-6. Epub 2025 Jun 10. PMID: 40513593.
* Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28;334(16):1442-1451. doi: 10.1001/jama.2025.15896. PMID: 40884491; PMCID: PMC12398767.
* Creus-Costa A, Andrés C, Vila J, González-Sánchez A, López N, Ortigosa-Gómez S, Caballero-Rabasco MA, González-Gómez de Agüero I, Velázquez Cerdà M, Lobato-Salinas Z, Trujillo-Isern G, Conti R, Coma-Calle M, Visa-Reñé N, Flores-Villar S, Rius-Gordillo N, Geronès L, Pujol-Soler B, Ruiz-García M, de Haan-Bosch M, Antón A, Soler-Palacín P, Soriano-Arandes A, Col·laboració Pediàtrica de Catalunya (COPEDICAT) network. Decline in pediatric respiratory syncytial virus hospitalizations following nirsevimab implementation: A multicenter, three-season observational study. Int J Infect Dis. 2025 Dec;161:108170. doi: 10.1016/j.ijid.2025.108170. Epub 2025 Nov 1. PMID: 41177442.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.